


What is claimed is:

1. A compound having the structure



wherein L is NH or O;


R₁ is a saturated or unsaturated, substituted or unsubstituted, straight or branched chain of 0-10 carbon or hetero atoms;

X is a linker group consisting of 0-2 substituted or unsubstituted aromatic rings or aliphatic linking groups containing 0-10 carbon or hetero atoms; and

Y is an activated ester, maleimido group, thiol, or NH-Z where Z is a carrier or a label.

2. The compound of claim 1 wherein the carrier is selected from the group consisting of poly(amino acid)s, polysaccharides, poly(nucleic acid)s, and particles.
3. The compound of claim 1 wherein the label is selected from the group consisting of enzymes, enzyme fragments, radioactive isotopes, enzyme substrates, enzyme inhibitors, coenzymes, fluorogenic compounds, chemiluminescent materials, electrochemical mediators, reporter groups, nucleic acids and particles.
4. The compound of claim 1 wherein Y is an activated ester selected from the group consisting of N-hydroxysuccinimidyl, *p*-nitrophenyl, pentafluorophenyl, and N-hydroxybenzotriazolyl esters.

5. An antibody produced in response to a compound having the structure



wherein L is NH or O;

R_1 is a saturated or unsaturated, substituted or unsubstituted, straight or branched chain of 0-10 carbon or hetero atoms;

X is a linker group consisting of 0-2 substituted or unsubstituted aromatic rings or aliphatic linking groups containing 0-10 carbon or hetero atoms; and

Y is NH-Z where Z is a carrier selected from the group consisting of poly(amino acid)s, polysaccharides, poly(nucleic acid)s, and particles.

6. A monoclonal antibody specific for efavirenz characterized by having less than 1 percent cross-reactivity with one or more protease inhibitors selected from the group consisting of nelfinavir, saquinavir, indinavir, ritonavir, amprenavir, lopinavir, and atazanavir.
7. A monoclonal antibody specific for efavirenz characterized by having less than 1 percent cross-reactivity with one or more nucleoside reverse transcriptase inhibitors selected from the group consisting of 3'-azido-3'-deoxythymidine and 2',3'-didehydro-3'-deoxythymidine.
8. A monoclonal antibody specific for efavirenz characterized by having less than 1 percent cross-reactivity with one or more non-nucleoside reverse transcriptase inhibitors selected from the group consisting of nevirapine and delaviradine.

9. A monoclonal antibody specific for efavirenz characterized by having less than 1 percent cross-reactivity with one or more protease inhibitors selected from the group consisting of nelfinavir, saquinavir, indinavir, ritonavir, amprenavir, lopinavir, and atazanavir.
10. Cell line EFA 97.1, ATCC designation _____, producing a monoclonal antibody having specificity for efavirenz.
11. A monoclonal antibody produced from cell line EFA 97.1, ATCC designation _____, the antibody having specificity for efavirenz.
12. A monoclonal antibody having specificity for efavirenz and binding in a manner equivalent to that of an antibody from cell line EFA 97.1, ATCC designation _____.
13. The 6-hydroxy analog of efavirenz having the structure:

